BACKGROUND: Multiple sclerosis has been associated with progressive brain volume loss. OBJECTIVE: We aimed to systematically summarize reported rates of brain volume loss in multiple sclerosis and explore associations between brain volume loss and markers of disease severity. METHODS: A systematic literature search (2003-2013) was conducted to identify studies with ≥12months of follow-up, reported brain volume measurement algorithms, and changes in brain volume. Meta-analysis random-effects models were applied. Associations between brain volume change, changes in lesion volume and disease duration were examined in pre-specified meta-regression models. RESULTS: We identified 38 studies. For the meta-analysis, 12 studies that reported annualized percentage brain volume change (PBVC), specified first-generation disease-modifying treatments (e.g., interferon-beta or glatiramer acetate) and used Structural Image Evaluation of Normalized Atrophy algorithm were analyzed. The annualized PBVC ranged from -1.34% to -0.46% per year. The pooled PBVC was -0.69% (95% CI=-0.87% to -0.50%) in study arms receiving first-generation disease-modifying treatments (N=6 studies) and -0.71% (95% CI=-0.81% to -0.61%) in untreated study arms (N=6 studies). CONCLUSIONS: In this study, the average multiple sclerosis patient receiving first-generation disease-modifying treatment or no disease-modifying treatment lost approximately 0.7% of brain volume/year, well above rates associated with normal aging (0.1%-0.3% of brain volume/year).
BACKGROUND:Multiple sclerosis has been associated with progressive brain volume loss. OBJECTIVE: We aimed to systematically summarize reported rates of brain volume loss in multiple sclerosis and explore associations between brain volume loss and markers of disease severity. METHODS: A systematic literature search (2003-2013) was conducted to identify studies with ≥12months of follow-up, reported brain volume measurement algorithms, and changes in brain volume. Meta-analysis random-effects models were applied. Associations between brain volume change, changes in lesion volume and disease duration were examined in pre-specified meta-regression models. RESULTS: We identified 38 studies. For the meta-analysis, 12 studies that reported annualized percentage brain volume change (PBVC), specified first-generation disease-modifying treatments (e.g., interferon-beta or glatiramer acetate) and used Structural Image Evaluation of Normalized Atrophy algorithm were analyzed. The annualized PBVC ranged from -1.34% to -0.46% per year. The pooled PBVC was -0.69% (95% CI=-0.87% to -0.50%) in study arms receiving first-generation disease-modifying treatments (N=6 studies) and -0.71% (95% CI=-0.81% to -0.61%) in untreated study arms (N=6 studies). CONCLUSIONS: In this study, the average multiple sclerosispatient receiving first-generation disease-modifying treatment or no disease-modifying treatment lost approximately 0.7% of brain volume/year, well above rates associated with normal aging (0.1%-0.3% of brain volume/year).
Authors: E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; I Paunkoski; D P Ramasamy; D Silva; E Carl; D Hojnacki; C Kolb; B Weinstock-Guttman; R Zivadinov Journal: AJNR Am J Neuroradiol Date: 2018-11-22 Impact factor: 3.825
Authors: Christina J Azevedo; Steven Y Cen; Sankalpa Khadka; Shuang Liu; John Kornak; Yonggang Shi; Ling Zheng; Stephen L Hauser; Daniel Pelletier Journal: Ann Neurol Date: 2018-02-09 Impact factor: 10.422
Authors: Jiwon Oh; Daniel Ontaneda; Christina Azevedo; Eric C Klawiter; Martina Absinta; Douglas L Arnold; Rohit Bakshi; Peter A Calabresi; Ciprian Crainiceanu; Blake Dewey; Leorah Freeman; Susan Gauthier; Roland Henry; Mathilde Inglese; Shannon Kolind; David K B Li; Caterina Mainero; Ravi S Menon; Govind Nair; Sridar Narayanan; Flavia Nelson; Daniel Pelletier; Alexander Rauscher; William Rooney; Pascal Sati; Daniel Schwartz; Russell T Shinohara; Ian Tagge; Anthony Traboulsee; Yi Wang; Youngjin Yoo; Tarek Yousry; Yunyan Zhang; Nancy L Sicotte; Daniel S Reich Journal: Neurology Date: 2019-02-20 Impact factor: 9.910
Authors: Dejan Jakimovski; Niels Bergsland; Michael G Dwyer; Jesper Hagemeier; Deepa P Ramasamy; Kinga Szigeti; Thomas Guttuso; David Lichter; David Hojnacki; Bianca Weinstock-Guttman; Ralph H B Benedict; Robert Zivadinov Journal: Neurobiol Aging Date: 2020-02-08 Impact factor: 4.673
Authors: Susan J van Rensburg; Ronald van Toorn; Rajiv T Erasmus; Coenraad Hattingh; Clint Johannes; Kelebogile E Moremi; Merlisa C Kemp; Penelope Engel-Hills; Maritha J Kotze Journal: Metab Brain Dis Date: 2021-04-28 Impact factor: 3.584